D&D Pharmatech is a global biotech company in the clinical stage, which operates by funding the development of innovative medicines. The company achieves this through disease-specific subsidiary companies, which are guided by top-tier medical research faculty. This unique structure allows for the rapid translation of cutting-edge research into therapeutic products that can save lives.

The company's product pipeline is focused on a variety of indications, including neurodegenerative and fibrotic diseases. Additionally, D&D Pharmatech applies big data in its research and diagnostics of CNS drugs. The company is the parent of several U.S.-based companies, including Neuraly, Precision Molecular, Valted Seq, Theraly Fibrosis, and P4 Microbiome.

Founded in 2014 in Korea, D&D Pharmatech expanded to the U.S. through research and development collaborations with multiple scientific co-founders from both academia and industry. The company is involved in the discovery and preclinical stages of various diseases and conditions, such as stroke, Parkinson's, obesity, NASH, type 2 diabetes, and oncology.

D&D Pharmatech's business model is based on funding the development of innovative medicines through its subsidiary companies. The company makes money by developing and commercializing these therapeutic products for patients suffering from a range of diseases.

Keywords: Biotech, Clinical-stage, Disease-specific subsidiaries, Therapeutic products, Neurodegenerative diseases, Fibrotic diseases, Big data, CNS drug research, Diagnostics, Research and development collaborations.